With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future [Yahoo! Finance]
Nautilus Biotechnology, Inc. (NAUT)
Company Research
Source: Yahoo! Finance
Institutions own 20% of Nautilus Biotechnology If you want to know who really controls Nautilus Biotechnology, Inc. ( NASDAQ:NAUT ), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 32% to be precise, is individual insiders. Put another way, the group faces the maximum upside potential (or downside risk). So, insiders of Nautilus Biotechnology have a lot at stake and every decision they make on the company's future is important to them from a financial point of view. In the chart below, we zoom in on the different ownership groups of Nautilus Biotechnology. View our latest analysis for Nautilus Biotechnology Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. We can see that Nautilus Biotechnology does have institutional investors; and they hold a good portion of the
Show less
Read more
Impact Snapshot
Event Time:
NAUT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAUT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAUT alerts
High impacting Nautilus Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
NAUT
News
- Nautilus Biotechnology, Inc. (NASDAQ: NAUT) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $1.75 price target on the stock.MarketBeat
- Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator AwardGlobeNewswire
- Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare ConferenceGlobeNewswire
- Nautilus Biotechnology Reports Third Quarter 2024 Financial ResultsGlobeNewswire
- Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024GlobeNewswire
NAUT
Earnings
- 10/29/24 - Beat
NAUT
Sec Filings
- 12/17/24 - Form 144
- 12/9/24 - Form 144
- 12/3/24 - Form 144
- NAUT's page on the SEC website